ANLON HEALTHCARE LIMITED (NSE: AHCL, BSE: 544497) is a Rajkot, Gujarat-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹1,432 Cr, it ranks #1,412 by market cap among the 6,197 Indian listed companies on FinBizNet, and #41 of 86 in Medicinal Chemicals and Botanical Products. At ₹27.03 (as of 16 Nov 2026), the share price is 27.4% below its 52-week high of ₹37.24 and 149.8% above its 52-week low of ₹10.82. The share price is up 93.6% over one year and up 89.1% over three months.
| Current Price | ₹27.03 |
|---|---|
| Market Cap | ₹1,432 Cr |
| NSE Symbol | AHCL |
| BSE Code | 544497 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 44.6 |
| Return on Equity | 11.42% |
| Return on Assets | 10.43% |
| 52-Week Range | ₹10.82 – ₹37.24 |
| 1-Year Price Change | +93.6% |
| 3-Month Price Change | +89.1% |
| Beta (1Y) | 0.42 |
| Headquarters | Rajkot, Gujarat |
| Website | www.anlon.in |
| Revenue | ₹106 Cr |
|---|---|
| Net Profit | ₹17 Cr |
| Net Margin | 16.3% |
| EPS (Basic) | ₹0.32 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
ANLON HEALTHCARE LIMITED reported revenue of ₹106 Cr in Q2 FY27, up 20.6% from ₹88 Cr in Q1 FY27. It posted a net profit of ₹17 Cr for the quarter, against a net profit of ₹8 Cr in Q1 FY27 (up 107.5%).
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹106 Cr | ₹17 Cr | 16.3% |
| Q1 FY27 | ₹88 Cr | ₹8 Cr | 9.5% |
| Q4 FY26 | ₹51 Cr | ₹11 Cr | 21.8% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 52.68% of ANLON HEALTHCARE LIMITED's shares as of Sept 2026, unchanged from Sept 2025. Delivery averaged 49.4% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Anlon Healthcare Limited manufactures and sells advance pharmaceutical intermediates in India and internationally. The company offers active pharmaceutical ingredients (API); nutraceutical API products; personal care ingredients; and veterinary API products. Its products are used in anti-inflammatory (NSAID), analgesic, antipyretic, antihistamine, antidepressant, antipsychotic, anticoagulant, antihypertensive, nutrition, anti-arrhythmic, anti-hyper parathyroid, antiplatelet, ant diabetic, gastroesophageal reflux disease (GERD), and anti-rheumatic therapeutics areas. The company was incorporated in 2013 and is based in Rajkot, India.
1. Manufacturing and Sale of Active Pharmaceutical Ingredients (APIs)-This segment manufactures and sells advance pharmaceutical intermediates. 2. NA-NA 3. NA-NA 4. NA-NA
1. Manufacturing and Sale of Active Pharmaceutical Ingredients (APIs)-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| ANLON HEALTHCARE LIMITED | ₹1,432 Cr | 44.6 | 11.42% | ₹106 Cr | +93.6% |
Listed by market capitalisation. Ratios are shown for context only.
ANLON HEALTHCARE LIMITED is trading at ₹27.03, with a market capitalisation of ₹1,432 Cr.
ANLON HEALTHCARE LIMITED operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
ANLON HEALTHCARE LIMITED has a P/E of 44.6 and a return on equity of 11.42%.
ANLON HEALTHCARE LIMITED is listed on the NSE under the symbol AHCL and on the BSE under the scrip code 544497.
ANLON HEALTHCARE LIMITED's share price is up 93.6% over one year and up 89.1% over three months. Its 52-week range is ₹10.82 to ₹37.24.
In Q2 FY27, ANLON HEALTHCARE LIMITED reported revenue of ₹106 Cr and net profit of ₹17 Cr, with basic EPS of ₹0.32 (consolidated, parsed from the company's exchange filing).
Promoters held 52.68% of ANLON HEALTHCARE LIMITED's shares as of Sept 2026, unchanged from Sept 2025.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.